Levitee Labs is an emerging multidisciplinary integrative wellness company that’s redefining mental healthcare through a preventative, restorative, and transformative approach that includes evidence-based alternative medicines and novel psychedelic therapies.
Through a vertically integrated and disciplined M&A model, our core objective is a progressive push towards the introduction of novel treatment modalities, with a key focus on the integration of evidence-based psychedelic medicines and therapies. This model addresses the burden of inefficiencies prevalent within current clinical treatments, particularly those available to underserved patient populations.Investors
The growing economical, psychological and clinical burden of mental health, addiction, and chronic pain needs to be addressed. Our mission is to bridge the gap between what the system currently provides and what patients need. We are creating the future of integrative wellness, now.
Lost economic output due to mental health, substance use, and chronic pain disorders
Value of the global psychedelic market
1 in 3
Canadians meet the criteria for at least one mental or substance use disorder in their lifetime
1 in 4
Canadians aged 15 or older living with chronic pain
Increase in opioid-related deaths over the course of the first six months of the pandemic
Levitee Labs Commences Trading in U.S. Under Ticker LVTTFLearn more
Levitee Labs completes acquisition of superfoods provider Earth Circle Organics Chain
Levitee Labs appoints Dr Fady Hannah-Shmouni as its chief medical and scientific officer and president of Levitee Clinics and Pharmacies
ACT Medical Clinic sold to Vancouver-based Levitee Labs